Literature DB >> 15252324

Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations.

S Nicholas Agoff, Rochelle L Garcia, Barbara Goff, Elizabeth Swisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15252324     DOI： 10.1097/01.pas.0000131554.05732.cd

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN： 0147-5185            Impact factor:   6.394


× No keyword cloud information.
  12 in total

1.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

2.  Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).

Authors:  Stephanie L Wethington; Kay J Park; Robert A Soslow; Noah D Kauff; Carol L Brown; Fanny Dao; Ebunoluwa Otegbeye; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Douglas A Levine; Ginger J Gardner
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

3.  Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Authors:  Melinda S Yates; Larissa A Meyer; Michael T Deavers; Molly S Daniels; Elizabeth R Keeler; Samuel C Mok; David M Gershenson; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

4.  Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

Authors:  G Landon; J Stewart; M Deavers; K Lu; N Sneige
Journal:  Gynecol Oncol       Date:  2012-03-13       Impact factor: 5.482

5.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

Review 6.  Genetic risk and gynecologic cancers.

Authors:  Laura L Holman; Karen H Lu
Journal:  Hematol Oncol Clin North Am       Date:  2012-02       Impact factor: 3.722

7.  Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.

Authors:  Susan M Domchek; Tara M Friebel; Judy E Garber; Claudine Isaacs; Ellen Matloff; Rosalind Eeles; D Gareth Evans; Wendy Rubinstein; Christian F Singer; Stephen Rubin; Henry T Lynch; Mary B Daly; Jeffrey Weitzel; Patricia A Ganz; Gabriella Pichert; Olufunmilayo I Olopade; Gail Tomlinson; Nadine Tung; Joanne L Blum; Fergus Couch; Timothy R Rebbeck
Journal:  Breast Cancer Res Treat       Date:  2010-02-24       Impact factor: 4.872

Review 8.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

9.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Authors:  Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.